UPR/MDACC: Partnership for Excellence in Cancer Research (2 of 2)

总体来说 项目摘要/摘要 这次癌症研究卓越伙伴关系(伙伴关系)的竞争性续签 波多黎各大学(UPR)和德克萨斯大学MD安德森癌症中心(MDACC)将：1) 巩固、加强和扩大普遍定期审议和普遍定期审议之间的关系；和2)利用 普遍定期审议综合癌症中心转型过程中经验丰富的综合伙伴关系的优势 (UPRCCC)迈向一个长期的总体目标：承认UPRCCC为NCI指定的癌症中心。至 解决波多黎各和德克萨斯州一些最严重的癌症健康差距，该伙伴关系将 建立感染驱动的恶性肿瘤项目，促进职业发展和翻译科学 (影响)。此应用程序代表了一种伙伴关系，在这种伙伴关系中，两个机构通过共享不同的 在实施综合团队科学、外联、教育和职业生涯方面互惠互利的专业知识 发展倡议。为了促进UPRCCC向NCI指定的过渡，UPR PIs领导了 在千年发展目标方案的支持下制定具体目标。更新的具体目标是：1) 开发多学科研究组合，重点关注由感染驱动的健康差距 恶性肿瘤；2)增加在实验室和人群中寻求职业生涯的西班牙裔学生的数量- 以癌症研究为基础，培养出一大批临床医生、科学家和内科科学家，他们 专门从事癌症研究，重点是代表不足的少数族裔和 服务不足的社区；3)加强所有利益攸关方之间的可持续合作，以制定和 促进关键的社区外联、教育和干预措施，旨在降低癌症发病率和 强调接种疫苗预防恶性肿瘤相关感染，在PR，德克萨斯州， 和其他地方；4)利用与NCI指定的癌症中心的战略合作来增强 UPR和UPRCCC的癌症研究能力；以及5)提供专业支持和发展 通过a)管理；b)规划和评价；以及c)旨在 培育和优化伙伴关系的研究、教育和外联议程，以支持 NCI指定的癌症中心的目标。这项推进伙伴关系的申请的关键要素包括： 1)侧重于影响的多学科协作研究项目，代表了 翻译研究连续体；2)以癌症为重点的综合培训和职业发展核心； 3)发展双重MD/MPH学位，以应对影响不成比例的特定癌症 西班牙裔人口；4)建立、教育和倡导广泛的HPV疫苗接种计划的外联工作； 以及5)构建基础设施的DATAOmics核心。这一倡议将加强整个癌症研究 企业在PR和TX感染驱动的恶性肿瘤方面，并将支持实施 UPRCCC为NCI指定提交癌症中心支持拨款的路线图(第30页)。

OVERALL PROJECT SUMMARY / ABSTRACT This competitive renewal of the Partnership for Excellence in Cancer Research (Partnership) between the University of Puerto Rico (UPR) and the University of Texas MD Anderson Cancer Center (MDACC) will: 1) solidify, strengthen, and expand the relationship between UPR and MDACC; and 2) leverage the breadth and strengths of an experienced and integrated Partnership in transition of the UPR Comprehensive Cancer Center (UPRCCC) towards a long-term overall goal: recognition of UPRCCC as an NCI-designated cancer center. To address some of the most profound cancer health disparities in Puerto Rico and Texas, the Partnership will establish an Infection-Driven Malignancies Program for Advancing Careers and Translational Sciences (IMPACT). This application represents a partnership in which both institutions profit from sharing distinct expertise to mutually benefit in implementation of integrated team science, outreach, education and career development initiatives. To facilitate UPRCCC’s transition towards NCI-designation, the UPR PIs led the development of the specific aims with support of the MDACC PIs. The Specific Aims for the renewal are: 1) Develop a multidisciplinary research portfolio focused on health disparities derived from infection-driven malignancies; 2) Increase the number of Hispanic students pursuing careers in laboratory and population- based cancer research to produce a critical mass of clinicians, scientists, and physician-scientists, who specialize in cancer research, with emphasis on cancer health disparities in underrepresented minorities and underserved communities; 3) Strengthen sustainable collaborations among all the stakeholders to develop and promote key community outreach, education, and interventions aimed at reducing cancer rates and emphasizing vaccinations against malignancy linked infections, among Hispanic/Latino populations in PR, TX, and elsewhere; 4) Leverage strategic collaborations with NCI-designated cancer centers to augment the cancer research capacity of the UPR and the UPRCCC; and 5) Provide professional support and development tools through the a) Administration; b) Planning and Evaluation; and c) Shared Resources Cores designed to nurture and optimize the Partnership’s research, education, and outreach agendas in support of the long-term goal of an NCI-designated Cancer Center. Key elements of this application to advance the Partnership include: 1) Multidisciplinary collaborative research projects focused on IMPACT that represent stages of the translational research continuum; 2) A comprehensive cancer-focused training and career development core; 3) The development of a dual MD/MPH degree to address specific cancers disproportionately affecting Hispanic populations; 4) Outreach efforts to build, educate, and advocate for broad HPV vaccination programs; and 5) a DATAOmics Core that builds infrastructure. This initiative will strengthen the overall cancer research enterprise in infection-driven malignancies in both PR and TX, and will support the implementation of UPRCCC’s roadmap to submission of a Cancer Center Support Grant (P30) for NCI designation.